Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma

Journal of Clinical Oncology

Volumn 23, Issue 31, 2005, Pages 8048-8056

  Gimotty, Phyllis A ^a   Van Belle, Patricia ^b   Elder, David E ^b   Murry, Todd ^b   Montone, Kathleen T ^b   Xu, Xiaowei ^b   Hotz, Susan ^b   Raines, Shane ^b   Ming, Michael E ^b   Wahl, Peter ^b   Guerry, DuPont ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; MONOCLONAL ANTIBODY KI 67;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER GROWTH; CARCINOGENICITY; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MITOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN CANCER; COHORT ANALYSIS; COMPARATIVE STUDY; MELANOMA; METABOLISM; MIDDLE AGED; MITOSIS INDEX; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; SKIN TUMOR; SURVIVAL RATE; TUMOR ASSOCIATED LEUKOCYTE;

ADULT; AGED; AGED, 80 AND OVER; CELL PROLIFERATION; COHORT STUDIES; FEMALE; HUMANS; KI-67 ANTIGEN; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MIDDLE AGED; MITOTIC INDEX; PROGNOSIS; PROSPECTIVE STUDIES; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 32944479844     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.0735     Document Type: Article

References (34)

1. Clark WH, From L, Bernardino EA, et al: The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 29:705-727, 1969
2. Clark WH, Elder DE, Guerry D, et al: Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 81:1893-1904, 1989
3. Guerry D, Synnestvedt M, Elder DE, et al: Lessons learned from tumor progression: The invasive radial growth phase of melanoma is common, incapable of metastasis, and indolent. J Invest Dermatol 100:342S-345S, 1993
4. Elder DE, Murphy GF: Malignant Tumors (Melanomas and Related Lesions), in Elder DE, Murphy GF (eds): Melanocytic Tumors of the Skin. Washington, DC, Armed Forces Institute of Pathology, 1991, pp 103-154
5. Cook MG, Clarke TJ, Humphreys S, et al: A nationwide survey of observer variation in the diagnosis of thin cutaneous malignant melanoma including the MIN terminology. J Clin Pathol 50:202-205, 1997
6. McDermott NC, Hayes DP, al-Sader MH, et al: Identification of vertical growth phase in malignant melanoma: A study of interobserver agreement. Am J Clin Pathol 110:753-757, 1998
7. Oliveira Filho RS, Ferreira LM, Biasi LJ, et al: Vertical growth phase and positive sentinel node in thin melanoma. Braz J Med Biol Res 36:347-350, 2003
8. Cook MG, Spatz A, Brocker E, et al: Identification of histological features associated with metastatic potential of thin (< 1.0 mm) cutaneous melanoma with metastases: A study on behalf of the EORTC Melanoma Group. J Pathol 197:188-193, 2002
9. Lefevre M, Vergier B, Balme B, et al: Relevance of vertical growth pattern in thin level II cutaneous superficial spreading melanomas. Am J Surg Pathol 27:717-724, 2003
10. Massi D, Franchi A, Borgognoni L, et al: Thin cutaneous malignant melanomas (≤1.5 mm): Identification of risk factors indicative of progression. Cancer 85:1067-1076, 1999
11. Gimotty PA, Botbyl J, Soong SJ, et al: A population-based validation of the AJCC staging system for melanoma. J Clin Oncol (in press)
12. Balch CM, Buzaid AC, Soong SJ, et al: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635-3648, 2001
13. Gimotty PA, Guerry D, Ming M, et al: Thin primary cutaneous malignant melanoma: A prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer Staging. J Clin Oncol 22:3668-3676, 2004
14. Brown DC, Gatter KC: Ki67 protein: The immaculate deception? Histopathology 40:2-11, 2002
15. de Wit NJW, van Muijen GNP, Ruiter DJ: Immunohistochemistry in melanocytic proliferative lesions. Histopathology 44:517-541, 2004
16. Lomuto M, Calabrese P, Giuliani A: Prognostic signs in melanoma: State of the art. J Eur Acad Dermatol Venereol 18:291-300, 2004
17. Li N, Mangini J, Bhawan J: New prognostic factors of cutaneous melanoma: A review of the literature. J Cutan Pathol 29:324-340, 2002
18. Elder DE, Van Belle PA, Elenitsas R, et al: Neoplastic progression and prognosis in melanoma. Semin Cutan Med Surg 15:336-348, 1996
19. Reed RJ: Minimal deviation melanoma, in Mihm MC, Murphy GF, Kaufman N (eds): Pathobiology and Recognition of Malignant Melanoma. Baltimore, MD, Williams & Wilkins, 1988, pp 110-152
20. SAS Institute Inc: SAS/STAT User's Guide, Version 9.1. Cary, NC, SAS Institute Inc, 2004
21. Steinberg D, Colla P: CART: Tree-structured non-parametric data analysis. San Diego, CA, Salford Systems, 1995
22. Hazan C, Metzer K, Panageas KS, et al: Evaluation of the proliferation marker MIB-1 in the prognosis of cutaneous malignant melanoma. Cancer 95:634-640, 2002
23. Alonso SR, Ortiz P, Pollan M, et al: Progression in cutaneous malignant melanoma is associated with distinct expression profiles: A tissue microarray-based study. Am J Pathol 164:193-203, 2004
24. Balch CM, Soong SJ, Gershenwald JE, et al: Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19:3622-3634, 2001
25. McKinnon JG, Yu XQ, McCarthy WH, et al: Prognosis for patients with thin cutaneous melanoma. Cancer 98:1223-1231, 2003
26. Mansson-Brahme E, Carstensen J, Erhardt K, et al: Prognostic factors in thin cutaneous malignant melanoma. Cancer 73:2324-2332, 1994
27. Finley JW, Gibbs JF, Rodriguez LM, et al: Pathologic and clinical features influencing outcome of thin cutaneous melanoma: Correlation with newly proposed staging system. Am Surg 66:527-531, 2000
28. Ostmeier H, Fuchs B, Otto F, et al: Can immunohistochemical markers and mitotic rate improve prediction in patients with primary melanoma? Cancer 85:2391-2399, 1999
29. Azzola MF, Shaw HM, Thompson JF, et al: Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma. Cancer 97:1488-1498, 2003
30. Francken AB, Shaw HM, Thompson JF, et al: The prognostic importance of tumor rnitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up. Ann Surg Oncol 11:426-433, 2004
31. Frahm S, Schubert C, Parwaresch R, et al: High proliferative activity may predict early metastasis of thin melanomas. Hum Pathol 32:1376-1381, 2001
32. Moretti S, Spallanzani A, Chiarugi A, et al: Correlation of Ki67 expression in cutaneous primary melanoma with prognosis in a prospective study: Different correlation according to thickness. J Am Acad Dermatol 44:188-192, 2001
33. Pepe MS, Etzioni R, Feng Z, et al: Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 93:1054-1061, 2001
34. Barker PE: Cancer biomarker validation: Standards and process. Ann N Y Acad Sci 983:142-150, 2003